Follicular Lymphoma
News
FDA approves idelalisib for CLL, SLL and FL
The drug was granted traditional approval for use in combination with rituximab to treat patients with relapsed CLL who cannot receive rituximab...
News
FDA approves idelalisib for three leukemia and lymphoma indications
News
Combo appears safe and active in CLL, NHL
Credit: Linda Bartlett KOHALA COAST, HAWAII—Early results of a small, phase 1 study suggest a novel combination treatment is active and generally...
News
Survival differences in blood cancers across Europe
Credit: Rhoda Baer Differences in treatment access and quality may explain why survival rates vary widely for European patients with hematologic...
Conference Coverage
Novel agent shows promising activity in heavily pretreated NHL
©ASCO/Rodney White CHICAGO—The novel, oral selective inhibitor of nuclear transport known as selinexor (KPT-330) can safely be given as...
News
PET-CT accurately predicts survival of follicular lymphoma patients
Key clinical point: For patients with follicular lymphoma, a PET-CT performed at the end of induction therapy is predictive of survival.Major...
News
Agricultural chemicals and the risk of NHL
EPA/John Messina After reviewing nearly 30 years’ worth of data, investigators have compiled a list of agricultural chemicals that appear to...
News
Younger men with goiter at higher risk for thyroid cancers
Key clinical point: Men under age 50 undergoing surgery for benign goiter are at elevated risk for thyroid cancer.Major finding: Among men under...
News
EC approves SC formulation of rituximab
The European Commission (EC) has approved a subcutaneous (SC) formulation of rituximab (MabThera) to treat patients with follicular lymphoma or...
News
Vorinostat demonstrates antitumor activity in FL
Single-agent treatment with the HDAC inhibitor vorinostat can be effective in certain patients with indolent non-Hodgkin lymphoma (NHL), according...